{
    "clinical_study": {
        "@rank": "43719", 
        "arm_group": [
            {
                "arm_group_label": "Morphine 6 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo Sublingual Spray (PSS) + Intravenous Morphine (IVM 6 mg), every 30 minutes for two hours as needed (or until rescue), maximum exposure morphine 30 mg"
            }, 
            {
                "arm_group_label": "Fentanyl 100 \u00b5g", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 100 \u00b5g), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 500 \u00b5g"
            }, 
            {
                "arm_group_label": "Fentanyl 200 \u00b5g", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 200 \u00b5g), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 1000 \u00b5g"
            }, 
            {
                "arm_group_label": "Fentanyl 400 \u00b5g", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 400 \u00b5g), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 2000 \u00b5g"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will explore effectiveness of three doses of fentanyl sublingual spray against an\n      active comparator in emergency department (ED) patients with acute pain.\n\n      After screening, eligible participants will participate in a treatment period (up to 2\n      hours) and a post-treatment evaluation period (up to 4 hours or discharge from the ED).\n      Open-label standard of care rescue medication for pain can be given at any time during the\n      study period, based on clinical judgment of the treating physician.\n\n      Adverse events will be collected for five days after initial enrollment."
        }, 
        "brief_title": "Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Pain", 
        "condition_browse": {
            "mesh_term": "Emergencies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Is able to understand the language in which the study is being conducted and has\n             provided meaningful written informed consent for the study\n\n          -  Has an acute painful condition requiring parenteral analgesia as deemed necessary by\n             the treating physician or physician extender\n\n          -  Has a pain score within protocol-specified parameters\n\n        Exclusion Criteria:\n\n          -  Has allergy to fentanyl or morphine\n\n          -  Has oxygen-dependent conditions or oxygen saturation <95%\n\n          -  Has planned or recent drug use outside protocol-specified parameters\n\n          -  Has any condition that, in the principal investigator's opinion, would place the\n             patient at risk or influence the conduct of the study or interpretation of results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "176", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137525", 
            "org_study_id": "INS-14-022"
        }, 
        "intervention": [
            {
                "arm_group_label": "Morphine 6 mg", 
                "description": "Intravenous infusion - delivering morphine 6 mg", 
                "intervention_name": "Morphine 6 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "IVM 6 mg", 
                    "Standard of Care"
                ]
            }, 
            {
                "arm_group_label": "Fentanyl 100 \u00b5g", 
                "description": "Fentanyl sublingual spray  - single unit delivering 100 \u00b5g fentanyl", 
                "intervention_name": "Fentanyl 100 \u00b5g", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FSS 100 \u00b5g", 
                    "SUBSYS\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Fentanyl 200 \u00b5g", 
                "description": "Fentanyl sublingual spray - single unit delivering 200 \u00b5g fentanyl", 
                "intervention_name": "Fentanyl 200 \u00b5g", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FSS 200 \u00b5g", 
                    "SUBSYS\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Fentanyl 400 \u00b5g", 
                "description": "Fentanyl sublingual spray - single unit delivering 400 \u00b5g fentanyl", 
                "intervention_name": "Fentanyl 400 \u00b5g", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FSS 400 \u00b5g", 
                    "SUBSYS\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Morphine 6 mg", 
                "description": "Matching sublingual spray - single unit delivering 0 \u00b5g fentanyl", 
                "intervention_name": "Placebo Sublingual Spray", 
                "intervention_type": "Drug", 
                "other_name": "PSS"
            }, 
            {
                "arm_group_label": [
                    "Fentanyl 100 \u00b5g", 
                    "Fentanyl 200 \u00b5g", 
                    "Fentanyl 400 \u00b5g"
                ], 
                "description": "Matching intravenous infusion - delivering 0 mg morphine", 
                "intervention_name": "Intravenous Placebo", 
                "intervention_type": "Drug", 
                "other_name": "IVP"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fentanyl", 
                "Morphine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37235"
                }, 
                "name": "Vanderbilt University"
            }, 
            "investigator": {
                "last_name": "Sean Collins, MD, MSc, FACC, FAHA", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Multicenter, Double-Blind, Double Dummy, Active Comparator, Dose-Ranging Study to Explore the Efficacy of SUBSYS\u00ae in Emergency Department Patients With Acute Pain", 
        "overall_contact": {
            "last_name": "Melissa Ortiz Alvidrez", 
            "phone": "1-512.351.9805"
        }, 
        "overall_official": [
            {
                "affiliation": "Vanderbilt University", 
                "last_name": "Sean Collins, MD, MSc, FACC, FAHA", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "INSYS Therapeutics Inc", 
                "last_name": "Giovanni DeCastro", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of participants requiring additional doses of randomized pain medication", 
            "safety_issue": "No", 
            "time_frame": "at 30 minutes after initial treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137525"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants requiring additional doses of randomized pain medication at secondary time points", 
                "safety_issue": "No", 
                "time_frame": "within 120 minutes after initial treatment"
            }, 
            {
                "measure": "Visual analogue scale (VAS) Summed Pain Intensity Difference (SPID) calculated as Area under the Curve (AUC) every 30 minutes", 
                "safety_issue": "No", 
                "time_frame": "from baseline through 120 minutes after the initial dose of investigational product"
            }, 
            {
                "measure": "Number of Investigational Product (IP) administrations", 
                "safety_issue": "No", 
                "time_frame": "within 120 minutes after initial treatment"
            }, 
            {
                "measure": "Time to onset of pain relief (in minutes) using the stopwatch method", 
                "safety_issue": "No", 
                "time_frame": "within 120 minutes after first treatment"
            }, 
            {
                "measure": "Richmond Agitation Sedation Scale (RASS) score", 
                "safety_issue": "No", 
                "time_frame": "within 120 minutes after first treatment"
            }, 
            {
                "measure": "Percentage of Participants requiring rescue medication", 
                "safety_issue": "No", 
                "time_frame": "during the 5-day study period"
            }, 
            {
                "measure": "Time until rescue medication was required", 
                "safety_issue": "No", 
                "time_frame": "during the 5-day study period"
            }, 
            {
                "measure": "Percentage of participants experiencing a treatment-related adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "during the 5-day study period"
            }, 
            {
                "measure": "Percentage of participants with clinically significant changes in vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "during the 5-day study period"
            }
        ], 
        "source": "INSYS Therapeutics Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "INSYS Therapeutics Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}